Fundz

Minerva Biotechnologies Corp reported raising $4.23 Million in an initial SEC Form D filing, from an offering of $12 Million

PRIVATEApr 05, 2019$4.2M of $12M raised

Amount Raised

$4.23 Million

$4.23 Million sold, per SEC Form D (first sale Apr 5, 2019)

Round Type

Venture

WalthamBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Minerva Biotechnologies that raised within 45 days of this round, from Fundz verified event records.

  • Finch Therapeutics Group, Inc. raised $23M on May 20, 2019.
  • Scipher Medicine raised $20M on May 20, 2019.
  • Therini Bio raised $2.4M (Seed) on May 17, 2019.
  • Anelixis Therapeutics, Inc. raised $1M (Seed) on May 17, 2019.
  • SynerFuse, Inc. raised $2.6M (Seed) on May 17, 2019.
  • Vivos Therapeutics raised $557K (Seed) on May 16, 2019.

Who to call at Minerva Biotechnologies, and when

A new round usually means Minerva Biotechnologies is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Minerva Biotechnologies raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Minerva Biotechnologies, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Minerva Biotechnologies. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Minerva Biotechnologies

Location

40 BEAR HILL ROAD

Waltham, Massachusetts, United States

About

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Minerva Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsCynthia B., Executive Officer, Director hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Minerva Biotechnologies's next move

See what Strategic adds

Minerva Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.